ReviewCurrent cardiology reports2010
Echocardiographic quantification of left ventricular mass: prognostic implications.
Review in Current cardiology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Artificial intelligence-based myocardial texture analysis in etiological differentiation of left ventricular hypertrophy.Annals of translational medicine · 2021Article
- Cross-Sectional Associations between Homoarginine, Intermediate Phenotypes, and Atrial Fibrillation in the Community-The Gutenberg Health Study.Biomolecules · 2018Article
- Feature Tracking Cardiac MRI Reveals Abnormalities in Ventricular Function in Patients With Bicuspid Aortic Valve and Preserved Ejection Fraction.Tomography (Ann Arbor, Mich.) · 2018Article
- QTc dispersion and Cornell duration product can predict 10-year outcomes in hypertensive patients with left ventricular hypertrophy.Clinical cardiology · 2017Article
- Left heart morphology and function in primary aldosteronism.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2012Review
- Association of left ventricular mass with all-cause mortality, myocardial infarction and stroke.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular hypertrophy (LVH) has been shown to be an independent risk factor for adverse cardiac and cerebrovascular events. Despite this well-known association, the lack of a standardized approach for the quantification and the monitoring of LVH regression has limited its use as a primary risk factor that can be easily clinically targeted. Echocardiography has become the most widespread tool used for the quantification of LVH. With advances in this technology, echocardiographic quantification of LVH has improved and reference standards are being used to determine the clinical implications of LVH regression. In this article, we aim to provide a current appraisal of LVH with a focus on presenting the current clinical methods used to accurately detect LVH, the prognostic implications of these findings, and help develop a therapeutic target for clinicians.
Indexed as
Identifiers
20424973What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.